Oligest Dosage/Direction for Use

The dosage of OLIGEST is one tablet daily without any break, taken preferably at the same time each day with some liquid as needed. The tablet can be taken with or without food. Tablets must be taken continuously without regard to vaginal bleeding.
When a pack is finished the next one should be started without interruption. Treatment can be started on any day of the menstrual cycle. Any hormonal contraception needs to be stopped prior to initiation of dienogest. If contraception is required, non-hormonal methods of contraception should be used (e.g. barrier method).
Management of missed tablets: The efficacy of OLIGEST may be reduced in the event of missed tablets, vomiting and/or diarrhea (if occurring within 3-4 hours after tablet taking). In the event of one or more missed tablets, the woman should take one tablet only, as soon as she remembers, and should then continue the next day at her usual time. A tablet not absorbed due to vomiting or diarrhea should likewise be replaced by one tablet.
Additional Information on Special Populations: Paediatric Population: Dienogest is not indicated in children prior to menarche.
Adolescent Population: The safety and efficacy of dienogest was investigated in clinical trial over 12 months in 111 adolescent women (12-18 years) with clinically suspected or confirmed endometriosis. The use of dienogest in adolescents over a treatment period of 12 months was associated with a mean decrease in BMD in the lumbar spine of 1.2%. After cessation of treatment, BMD increased towards pre-treatment levels in majority of these patients.
Therefore, the treating physician should weigh the benefits of dienogest against the possible risks of use in each individual adolescent patient and re-evaluate on a regular basis. (See Precautions and Pharmacology: Pharmacodynamics under Actions).
Geriatric Population: There is no relevant indication for use of dienogest in the post menopause.
Patients with Hepatic Impairment: Dienogest is contraindicated in patients with present or past severe hepatic disease (see Contraindications).
Patients with Renal Impairment: There are no data suggesting the need for a dosage adjustment in patients with renal impairment.